Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443088 | 1.00 | TRPV1 (0.55) | TRPV1OPRM1LMNATP53MAPT | |
| SCHEMBL4452833 | 1.00 | TRPV1 (0.55) | TRPV1OPRM1LMNATP53MAPT | |
| SCHEMBL4442121 | 0.99 | TRPV1 (0.55) | TRPV1OPRM1LMNATP53MAPT | |
| SCHEMBL4441373 | 0.99 | TRPV1 (0.55) | TRPV1OPRM1LMNATP53MAPT | |
| SCHEMBL13753768 | 0.95 | TRPV1 (0.55) | TRPV1OPRM1LMNAMAPT | |
| SCHEMBL4444559 | 0.93 | TRPV1 (0.59) | TRPV1OPRM1LMNATP53MAPT | |
| SCHEMBL13753771 | 0.93 | TRPV1 (0.54) | TRPV1OPRM1MAPT | |
| SCHEMBL4442130 | 0.93 | TRPV1 (0.54) | TRPV1OPRM1MAPT | |
| SCHEMBL13753770 | 0.93 | TRPV1 (0.54) | TRPV1OPRM1 | |
| SCHEMBL4446846 | 0.92 | TRPV1 (0.60) | TRPV1OPRM1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | claimed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | claimed |
| EP-1572632-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | XENTION LTD (GB) | 2008-08-13 | — | — | EP | claimed |
| US-20060135505-A1 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | BAYER HEALTHCARE AG (DE) | 2006-06-22 | — | — | US | claimed |
| EP-1572632-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | claimed |
| WO-2004052845-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | claimed |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| EP-1572632-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | XENTION LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20060135505-A1 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | BAYER HEALTHCARE AG (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135505-A1 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | OPRL1, PTGER1, LTB4R2 | TRPV1 8/4885OPRM1 36/4885LMNA 3132/4885 |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | OPRL1, TRPV1, LTB4R | TRPV1 2/4885OPRM1 107/4885LMNA 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.